STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

Autor: Armand de Gramont, Marine Hug de Larauze, Thierry André, Pierre Laurent-Puig, Christophe Tournigand, Magdalena Benetkiewicz, Dominique Notelet, Aimery de Gramont, Alexandra Hadengue, Jérôme Paget, Franck Bonnetain, Benoist Chibaudel

Publikováno v: BMC Cancer
BMC Cancer, BioMed Central, 1910, 15, pp.496. 〈10.1186/s12885-015-1503-7〉
BMC Cancer, BioMed Central, 1910, 15, pp.496. ⟨10.1186/s12885-015-1503-7⟩
BMC Cancer, 2015, 15, pp.496. ⟨10.1186/s12885-015-1503-7⟩
Bmc Cancer, vol. 15, pp. 496

Background The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f3f6206e1b084065c060aec3107cee8
https://doi.org/10.1186/s12885-015-1503-7

BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC

Autor: Olivier Scatton, Maxime Ronot, Jacques Belghiti, Eric Vibert, Laetitia Fartoux, Valérie Paradis, Armand de Gramont, Annemilaï Tijeras-Raballand, Charlotte Costentin, Eric Raymond, Sandrine Faivre, M. Granier, Alexandra Hadengue, David Brusquant, Mohamed Bouattour, Olivier Soubrane, Olivier Rosmorduc, Benoist Chibaudel, Dominique Wendum

Publikováno v: Journal of Clinical Oncology. 34:252-252

252 Background: This open-label, multicenter, phase II study aimed at investigating the activity of sorafenib including radiological, pathological and biological changes in tumor from patients with resectable HCC. Methods: Preoperative administration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c96fe2b0511049ab7d6381c15c455e59
https://doi.org/10.1200/jco.2016.34.4_suppl.252

Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results

Autor: Jean-François Seitz, Sandrine Faivre, Alexandre Amin, Annemilaï Tijeras-Raballand, David Malka, Laetitia Fartoux, Philippe Bourget, Maxime Ronot, Mohamed Bouattour, Benoist Chibaudel, Eric Raymond, Alexandra Hadengue, Nelly Roldan, Armand de Gramont, Chantal Dreyer, Cindy Neuzillet, Gérard Lledo

Publikováno v: Journal of Clinical Oncology. 33:343-343

343 Background: There is no validated option beyond gemcitabine plus platinum standard first-line combination for advanced cholangiocarcinoma (CK). Second-line 5FU-based chemotherapy yields a median progression-free survival (PFS) and overall surviva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b34731e021b9399f8b5a7efe163b141
https://doi.org/10.1200/jco.2015.33.3_suppl.343

Second Line Therapy with Sunitinib As Single Agent in Patients with Advanced Intrahepatic Cholangiocarcinoma (Update on Sun-Ck Phase Ii Trial)

Autor: N. Roldan, A. de Gramont, Laetitia Fartoux, Annemilaï Tijeras-Raballand, Eric Raymond, J.F. Seitz, S. Faivre, Alexandre Amin, Mohamed Bouattour, Benoist Chibaudel, Maxime Ronot, Gérard Lledo, Cindy Neuzillet, Alexandra Hadengue, Philippe Bourget, Chantal Dreyer, David Malka

Publikováno v: Annals of Oncology. 25:iv244

Aim: Beyond platinum-based first line chemotherapy for advanced cholangiocarcinoma (CK), second line 5FU-based treatments yield median progression-free survival (PFS) of Methods: This multicenter phase 2 study enrolled pts with locally advanced intra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fde2e307beedf20e4ffc91f27e3ab4e1
https://doi.org/10.1093/annonc/mdu334.105

CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC)

Autor: Jean-Pierre Delord, Michel Gatineau, Eric Raymond, Jérôme Fayette, Christophe Le Tourneau, Annemilaï Tijeras-Raballand, Alexandra Hadengue, K. Slimane, M. Granier, Nasredine Aissat, Sebastien Albert, Benoist Chibaudel, Sandrine Faivre, Chantal Dreyer

Publikováno v: Journal of Clinical Oncology. 31:6036-6036

6036 Background: ThePI3K/mTOR pathway is activated in >50% of HNSCC with preclinical synergism between everolimus and carboplatin/paclitaxel. Methods: Patients (pts) with untreated locally advanced HNSCC with ECOG PS2) followed by chemoradiotherapy.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::692dbcc4217ec1a30b193acf544ecc24
https://doi.org/10.1200/jco.2013.31.15_suppl.6036